174 related articles for article (PubMed ID: 20002303)
21. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens.
Kuzushita N; Gregory SH; Monti NA; Carlson R; Gehring S; Wands JR
Gastroenterology; 2006 Feb; 130(2):453-64. PubMed ID: 16472599
[TBL] [Abstract][Full Text] [Related]
22. Cellular immunogenicity of a multi-epitope peptide vaccine candidate based on hepatitis C virus NS5A, NS4B and core proteins in HHD-2 mice.
Huang XJ; Lü X; Lei YF; Yang J; Yao M; Lan HY; Zhang JM; Jia ZS; Yin W; Xu ZK
J Virol Methods; 2013 Apr; 189(1):47-52. PubMed ID: 23333413
[TBL] [Abstract][Full Text] [Related]
23. CD4(+) T-cell activation is differentially modulated by bacteria-primed dendritic cells, but is generally down-regulated by n-3 polyunsaturated fatty acids.
Brix S; Lund P; Kjaer TM; Straarup EM; Hellgren LI; Frøkiaer H
Immunology; 2010 Mar; 129(3):338-50. PubMed ID: 19909377
[TBL] [Abstract][Full Text] [Related]
24. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial).
Chernykh E; Leplina O; Oleynik E; Tikhonova M; Tyrinova T; Starostina N; Ostanin A
Immunol Res; 2018 Feb; 66(1):31-43. PubMed ID: 29164490
[TBL] [Abstract][Full Text] [Related]
26. Induction of hepatitis C virus-specific cytotoxic T and B cell responses by dendritic cells expressing a modified antigen targeting receptor.
Wang QC; Feng ZH; Zhou YX; Nie QH
World J Gastroenterol; 2005 Jan; 11(4):557-60. PubMed ID: 15641145
[TBL] [Abstract][Full Text] [Related]
27. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
28. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice.
Guan J; Deng Y; Chen H; Yin X; Yang Y; Tan W
Arch Virol; 2015 Oct; 160(10):2517-24. PubMed ID: 26215441
[TBL] [Abstract][Full Text] [Related]
29. Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts.
Malowany JI; McCormick S; Santosuosso M; Zhang X; Aoki N; Ngai P; Wang J; Leitch J; Bramson J; Wan Y; Xing Z
Mol Ther; 2006 Apr; 13(4):766-75. PubMed ID: 16343993
[TBL] [Abstract][Full Text] [Related]
30. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
31. Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells.
Ou-Yang P; Hwang LH; Tao MH; Chiang BL; Chen DS
J Med Virol; 2002 Mar; 66(3):320-8. PubMed ID: 11793383
[TBL] [Abstract][Full Text] [Related]
32. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
33. IFN-alpha beta promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines.
Cho HJ; Hayashi T; Datta SK; Takabayashi K; Van Uden JH; Horner A; Corr M; Raz E
J Immunol; 2002 May; 168(10):4907-13. PubMed ID: 11994440
[TBL] [Abstract][Full Text] [Related]
34. Combination of three adjuvants enhances the immunogenicity of a recombinant protein containing the CTL epitopes of non-structural proteins of hepatitis C virus.
Kuprianov VV; Nikolaeva LI; Zykova AA; Dedova AV; Grishechkin AE; Kapustin IV; Kotlyarov RY; Ravin NV
Virus Res; 2020 Jul; 284():197984. PubMed ID: 32325116
[TBL] [Abstract][Full Text] [Related]
35. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
[TBL] [Abstract][Full Text] [Related]
36. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
[TBL] [Abstract][Full Text] [Related]
37. Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection.
Encke J; Bernardin J; Geib J; Barbakadze G; Bujdoso R; Stremmel W
World J Gastroenterol; 2006 Nov; 12(44):7118-25. PubMed ID: 17131473
[TBL] [Abstract][Full Text] [Related]
38. TACI-BLyS signaling via B-cell-dendritic cell cooperation is required for naive CD8+ T-cell priming in vivo.
Diaz-de-Durana Y; Mantchev GT; Bram RJ; Franco A
Blood; 2006 Jan; 107(2):594-601. PubMed ID: 16195331
[TBL] [Abstract][Full Text] [Related]
39. Development of a dendritic cell vaccine encoding multiple cytotoxic T lymphocyte epitopes targeting hepatitis C virus.
Zhou Y; Zhao F; Chen L; Ma L; Wang Y; He Y; Ma Z; Liu H; Guo Y; Zhang Y; Yao Z; Hao C; Jia Z
Int J Mol Med; 2013 Oct; 32(4):901-9. PubMed ID: 23934073
[TBL] [Abstract][Full Text] [Related]
40. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
